The roles of cyclic AMP-ERK-Bad signaling pathways on 6-hydroxydopamine-induced cell survival and death in PC12 cells

Toxicology in Vitro

Volumn 27, Issue 8, 2013, Pages 2233-2241

  Park, Hyun Jin ^a   Park, Keun Hong ^a   Shin, Keon Sung ^a   Lee, Myung Koo ^a  

^a Chungbuk National University   (South Korea)

Author keywords

6 Hydroxydopamine; Bad; Cyclic AMP; Extracellular signal regulated kinase (ERK); PC12 cells

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CASPASE 3; CYCLIC AMP; MITOGEN ACTIVATED PROTEIN KINASE 1; OXIDOPAMINE; PROTEIN BAD; SERINE;

ARTICLE; CALCIUM CELL LEVEL; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROTOXICITY; OXIDATIVE STRESS; PHEOCHROMOCYTOMA CELL; PROTEIN CLEAVAGE; WESTERN BLOTTING;

6-HYDROXYDOPAMINE; BAD; CYCLIC AMP; EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK); PC12 CELLS;

ANIMALS; BCL-ASSOCIATED DEATH PROTEIN; CALCIUM; CASPASE 3; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIC AMP; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OXIDOPAMINE; PARKINSON DISEASE; PC12 CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; SIGNAL TRANSDUCTION;

EID: 84885817759     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2013.09.014     Document Type: Article

References (50)

1. Affaitati A., Cardone L., de Cristofaro T., Carlucci A., Ginsberg M.D., Varrone S., Gottesman M.E., Avvedimento E.V., Feliciello A. Essential role of A-kinase anchor protein 121 for cAMP signaling to mitochondria. J. Biol. Chem. 2003, 278:4286-4294.
2. Andrew R., Watson D.G., Best S.A., Midgley J.M., Wenlong H., Petty R.K. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. 1993, 18:1175-1177.
3. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Neurobiology 2001, 65:135-172.
4. Bonni A., Brunet A., West A.E., Datta S.R., Takasu M.A., Greenberg M.E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999, 286:1358-1362.
5. Cai B., Chang S.H., Becker E.B., Bonni A., Xia Z. P38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65. J. Biol. Chem. 2006, 281:25215-25222.
6. Canals S., Casarejos M.J., de Bernardo S., Solano R.M., Mena M.A. Selective and persistent activation of extracellular signal-regulated protein kinase by nitric oxide in glial cells induces neuronal degeneration in glutathione-depleted midbrain cultures. Mol. Cell. Neurosci. 2003, 24:1012-1026.
7. +-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J. Neurosci. Res. 1999, 57:86-94.
8. Choi W.S., Eom D.S., Han B.S., Kim W.K., Han B.H., Choi E.J., Oh T.H., Markelonis G.J., Cho J.W., Oh Y.J. Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and -9-mediated apoptotic pathways in dopaminergic neurons. J. Biol. Chem. 2003, 279:20451-20460.
9. Clark C.J., McDade D.M., O'Shaughnessyand C.T., Morris B.J. Contrasting roles of neuronal Msk1 and Rsk2 in Bad phosphorylation and feedback regulation of Erk signalling. J. Neurochem. 2007, 102:1024-1034.
10. Colucci-D'Amato L., Perrone-Capano C., di Porzio U. Chronic activation of ERK and neurodegenerative diseases. Bioessays 2003, 25:1085-1095.
11. Datta S.R., Katsov A., Hu L., Petros A., Fesik S.W., Yaffe M.B., Greenberg M.E. 14-3-3 proteins and survival kinases cooperate to in activate BAD by Bh3 domain phosphorylation. Mol. Cell 2000, 6:41-51.
12. De Chiara G., Marcocci M.E., Torcia M., Lucibello M., Rosini P., Bonini P., Higashimoto Y., Damonte G., Armirotti A., Amodei S., Palamara A.T., Russo T., Garaci E., Cozzolino F. Bcl-2 phosphorylation by p38 MAPK: identification of target sites and biologic consequences. J. Biol. Chem. 2006, 281:21353-21361.
13. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., Karin M., Davis R.J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994, 76:1025-1037.
14. Emerit J., Edeas M., Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. 2004, 58:39-46.
15. Ferrer I., Blanco R., Carmona M., Puig B., Barrachina M., Gomez C., Ambrosio S. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J. Neural Transm. 2001, 108:1383-1396.
16. Frodin M., Peraldi P., Van Obberghen E. Cyclic AMP activates the mitogen-activated protein kinase cascade in PC12 cells. J. Biol. Chem. 1994, 269:6207-6214.
17. Fujita N., Sato S., Tsuruo T. Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 2003, 278:49254-49260.
18. Hanrott K., Gudmunsen L., O'Neill M.J., Wonnacott S. 6-Hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase C delta. J. Biol. Chem. 2006, 281:5373-5382.
19. Hauge C., Frodin M. RSK and MSK in MAP kinase signalling. J. Cell. Sci. 2006, 119:3021-3023.
20. Hayakawa J., Ohmichi M., Kurachi H., Kanda Y., Hisamoto K., Nishio Y., Adachi K., Tasaka K., Kanzaki T., Murata Y. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000, 60:5988-5994.
21. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene 1999, 18:6087-6093.
22. Jin C.M., Yang Y.J., Huang H.S., Lim S.C., Kai M., Lee M.K. Induction of dopamine biosynthesis by L-DOPA in PC12 cells: implications of L-DOPA influx and cyclic AMP. Eur. J. Pharmacol. 2008, 591:88-95.
23. Jin C.M., Yang Y.J., Huang H.S., Kai M., Lee M.K. Mechanisms of L-DOPA-induced cytotoxicity in rat adrenal pheochromocytoma cells: implication of oxidative stress-related kinases and cyclic AMP. Neuroscience 2010, 170:390-398.
24. Kim K.S., Lee M.K., Carroll J., Joh T.H. Both the basal and inducible transcription of the tyrosine hydroxylase gene are dependent upon a cAMP response element. J. Biol. Chem. 1993, 268:15689-15695.
25. Korhonen L., Belluardo N., Mudo G., Lindholm D. Increase in Bcl-2 phosphorylation and reduced levels of BH3-only Bcl-2 family proteins in kainic acid-mediated neuronal death in the rat brain. Eur. J. Neurosci. 2003, 18:1121-1134.
26. Kulich S.M., Chu C.T. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J. Neurochem. 2001, 77:1058-1066.
27. Kulich S.M., Chu C.T. Role of reactive oxygen species in extracellular signal-regulated protein kinase phosphorylation and 6-hydroxydopamine cytotoxicity. J. Biosci. 2003, 28:83-89.
28. Kulich S.M., Horbinski C., Patel M., Chu C.T. 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic. Biol. Med. 2007, 43:372-383.
29. Lambeng N., Michel P.P., Agid Y., Ruberg M. The relationship between differentiation and survival in PC12 cells treated with cyclic adenosine monophosphate in the presence of epidermal growth factor or nerve growth factor. Neurosci. Lett. 2001, 297:133-136.
30. Lee H.J., Noh Y.H., Lee D.Y., Kim S.Y., Kim K.Y., Chunga Y.H., Lee W.B., Kim S.S. Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. Eur. J. Cell Biol. 2005, 84:897-905.
31. Li Z., Hu Y., Zhu Q., Zhua J. Neurotrophin-3 reduces apoptosis induced by 6-OHDA in PC12 cells through Akt signaling pathway. Int. J. Dev. Neurosci. 2008, 26:635-640.
32. Lin E., Cavanaugh J.E., Leak R.K., Perez R.G., Zigmond M.J. Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J. Neurosci. Res. 2008, 86:108-117.
33. Lipski J., Nistico R., Berretta N., Guatteo E., Bernardi G., Mercuri N.B. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?. Prog. Neurobiol. 2011, 94:389-407.
34. Maritim A.C., Sanders R.A., Watkins J.B. Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 2003, 17:24-38.
35. Marsden C.D. Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1994, 57:672-681.
36. Maundrell K., Antonsson B., Magnenat E., Camps M., Muda M., Chabert C., Gillieron C., Boschert U., Vial-Knecht E., Martinou J.C., Arkinstall S. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J. Biol. Chem. 1997, 272:25238-25242.
37. Montminy M. Transcriptional regulation by cyclic AMP. Ann. Rev. Biochem. 1997, 66:807-822.
38. Ochu E.E., Rothwell N.J., Waters C.M. Caspases mediate 6-hydroxydopamine-induced apoptosis but not necrosis in PC12 cells. J. Neurochem. 1998, 70:2637-2640.
39. Park K.H., Park H.J., Shin K.S., Choi H.S., Kai M., Lee M.K. Modulation of PC12 cell viability by forskolin-induced cyclic AMP levels through ERK and JNK pathways: An implication for L-DOPA-induced cytotoxicity in nigrostriatal dopamine neurons. Toxicol. Sci. 2012, 128:247-257.
40. Pedrosa R., Soares-da-Silva P. Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by l-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Br. J. Pharmacol. 2002, 137:1305-1313.
41. Quesada A., Lee B.Y., Micevych P.E. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev. Neurobiol. 2008, 68:632-644.
42. Rodriguez-Blanco J., Martin V., Herrera F., Garcia-Santos G., Antolin I., Rodriguez C. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine. J. Neurochem. 2008, 107:127-140.
43. Roux P.P., Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 2004, 68:320-344.
44. Sanchez S., Jimenez C., Carrera A.C., Diaz-Nido J., Avila J., Wandosell F. A cAMP-activated pathway, including PKA and PI3K, regulated neuronal differentiation. Neurochem. Int. 2004, 44:231-242.
45. Shimamura A., Ballif B.A., Richards S.A., Blenis J. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr. Biol. 2000, 10:127-135.
46. Stork P.J., Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell. Biol. 2002, 12:258-266.
47. Tan Y., Demeter M.R., Ruan H., Comb M.J. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J. Biol. Chem. 2000, 275:25865-25869.
48. Tischler A.S., Perlman R.L., Morse G.M., Sheard B.E. Glucocorticoid increase catecholamine synthesis and storage in PC12 pheochromocytoma cell cultures. J. Neurochem. 1983, 40:364-370.
49. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996, 87:619-628.
50. Zhu J.H., Kulich S.M., Oury T.D., Chu C.T. Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am. J. Pathol. 2002, 161:2087-2098.